Constellation Pharmaceuticals Inc (OQ:CNST)

Sector:  Healthcare Industry:  Biotechnology & Medical Research
See Regulatory Filings on SEC
Company Contact
Address: 215 1st St Ste 200
CAMBRIDGE MA 02142-1293
Tel: 1-617-7140539
IR: See website
Key People
Mark A. Goldsmith
Independent Chairman of the Board
Jigar Raythatha
President, Chief Executive Officer, Director
Emma Reeve
Chief Financial Officer, Senior Vice President, Treasurer
Adrian Senderowicz
Senior Vice President, Chief Medical Officer
Patrick Trojer
Chief Scientific Officer
Karen Higgins Valentine
Chief Legal Officer, General Counsel
Jessica Christo
Chief Product Development Officer
Business Overview
Constellation Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. The Company is primarily if focused on discovering and developing therapeutics that address serious unmet medical needs in patients with cancers associated with abnormal gene expression and drug resistance. The Company has two clinical-stage oncology development programs: the first program is evaluating a compound, CPI-1205, and the other program is evaluating a compound, CPI-0610.
Financial Overview
For the three months ended 31 March 2020, Constellation Pharmaceuticals Inc revenues was not reported. Net loss increased 31% to $25.4M. Higher net loss reflects Research and development - Balancing increase of 26% to $19.1M (expense), Interest Exp-Net of Capitalized Interest increase from $75K to $850K (expense), Stock-based Compensation in SGA increase of 97% to $1.6M (expense).
Employees: 106 as of Feb 29, 2020
Reporting Currency: U.S. Dollars
Enterprise value: $1,225M as of Mar 31, 2020
Annual revenue (TTM): $0.00M as of Mar 31, 2020
EBITDA (TTM): -$91.20M as of Mar 31, 2020
Net annual income (TTM): -$91.57M as of Mar 31, 2020
Free cash flow (TTM): -$80.45M as of Mar 31, 2020
Net Debt Last Fiscal Year: N/A
Shares outstanding: 41,838,071 as of Apr 30, 2020
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization